Adverse Effects of Androgen Deprivation Therapy on Persistent Genitourinary Complications After Carbon Ion Radiotherapy for Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 1, 2008, Pages 78-84

  Ishikawa, Hitoshi ^a,b   Tsuji, Hiroshi ^a   Kamada, Tadashi ^a   Hirasawa, Naoki ^a   Yanagi, Takeshi ^a   Mizoe, Jun Estu ^a   Akakura, Koichiro ^c   Suzuki, Hiroyoshi ^c   Shimazaki, Jun ^c   Nakano, Takashi ^b   Tsujii, Hirohiko ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carbon ion therapy; Dose volume histogram; Hormonal therapy; Prostate cancer; Urinary complications

Indexed keywords

DECISION MAKING; ELECTROTHERAPEUTICS; HEALTH; HEAVY IONS; IONS; MULTIVARIANT ANALYSIS; RADIOTHERAPY; RANDOM VARIABLES; REGRESSION ANALYSIS; RISK ASSESSMENT;

ACUTE GU TOXICITY; ANDROGEN DEPRIVATION THERAPY; CARBON ION RADIOTHERAPY; CARBON ION THERAPY; DOSE FRACTIONATION; DOSE-VOLUME HISTOGRAM; DOSIMETRIC PARAMETERS; GENITOURINARY (GU); GRAY EQUIVALENT; GU TOXICITY; HIGH-RISK PATIENTS; HORMONAL THERAPY; MULTI-VARIATE ANALYSIS; PHASE I; PHASE II; PROSTATE CANCER; RISK FACTORS; RISK GROUPS; URINARY COMPLICATIONS;

TOXICITY;

ANTIANDROGEN; GONADORELIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSIMETRY; HUMAN; ION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; SYMPTOM; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; CARBON RADIOISOTOPES; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RETROSPECTIVE STUDIES; RISK FACTORS; URETHRA; URINATION DISORDERS; UROGENITAL SYSTEM;

EID: 49549115523     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.12.044     Document Type: Article

References (51)

1. Nakata S., Takahashi H., Ohtake N., et al. Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 7 (2000) 254-257
2. Wang J.Z., Li X.A., Yu C.X., et al. The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys 57 (2003) 1101-1108
3. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
4. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
5. Kupelian P.A., Thakkar V.V., Khuntia D., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys 63 (2005) 1463-1468
6. Akimoto T., Muramatsu H., Takahashi M., et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 60 (2004) 1033-1039
7. Astrom L., Pedersen D., Mercke C., et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 74 (2005) 157-161
8. Vicini F.A., Vargas C., Edmundson G., et al. The role of high-dose rate brachytherapy in locally advanced prostate cancer. Semin Radiat Oncol 13 (2003) 98-108
9. Livsey J.E., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys 57 (2003) 1254-1259
10. Suzuki M., Kase Y., Yamaguchi H., et al. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams. Int J Radiat Oncol Biol Phys 48 (2000) 241-250
11. Kanai T., Furusawa Y., Fukutsu K., et al. Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res 147 (1997) 78-85
12. Kanai T., Endo M., Minohara S., et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 44 (1999) 201-210
13. Tsujii H., Mizoe J.E., Kamada T., et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol 73 (2004) 41-49
14. Akakura K., Tsujii H., Morita S., et al. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58 (2004) 252-258
15. Tsuji H., Yanagi T., Ishikawa H., et al. Hypofractionated radiotherapy with carbon ion beams prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1153-1160
16. Ishikawa H., Tsuji H., Kamada T., et al. Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study. Radiother Oncol 81 (2006) 57-64
17. Ishikawa H., Tsuji H., Kamada T., et al. Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1084-1091
18. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 685-698
19. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) 953-962
20. Fenwick J.D., Khoo V.S., Nahum A.E., et al. Correlations between dose-surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancer. Int J Radiat Oncol Biol Phys 49 (2001) 473-480
21. Herold D.M., Hanlon A.L., and Hanks G.E. Diabetes mellitus: A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 475-479
22. Cozzarini C., Fiorino C., Ceresoli G.L., et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 55 (2003) 688-694
23. Sobin L.H., Wittekind C., and International Union Against Cancer. TNM classification of malignant tumours. 5th ed. (1997), John Wiley & Sons, New York
24. Kuban D., Thames H., Levy L., et al. Failure definition-dependent differences in outcomes following radiation for localized prostate cancer: Can one size fit all?. Int J Radiat Oncol Biol Phys 61 (2005) 409-414
25. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
26. Kaplan E., and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
27. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41 (1998) 83-92
28. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
29. Peeters S.T., Hoogeman M.S., Heemsbergen W.D., et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1142-1152
30. Akimoto T., Katoh H., Noda S.E., et al. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Int J Radiat Oncol Biol Phys 63 (2005) 472-478
31. Merrick G.S., Butler W.M., Wallner K.E., et al. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy. Cancer J 10 (2004) 181-189
32. Salem N., Simonian-Sauve M., Rosello R., et al. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localized prostate cancer: A phase 2 study. Radiother Oncol 66 (2003) 159-165
33. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
34. 103Pd) combined with external beam radiation therapy. Int J Cancer 96 Suppl. (2001) 83-88
35. Yeoh E.E., Fraser R.J., McGowan R.E., et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: Early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 55 (2003) 943-955
36. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
37. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
38. Feigenberg S.J., Hanlon A.L., Horwitz E.M., et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 397-405
39. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
40. Vargas C., Ghilezan M., Hollander M., et al. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol 174 (2005) 882-887
41. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 3-11
42. Dockery F., Bulpitt C.J., Agarwal S., et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 104 (2003) 195-201
43. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 (2001) 4261-4267
44. Coia L.R., Myerson R.J., and Tepper J.E. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 31 (1995) 1213-1236
45. Sanguineti G., Marcenaro M., Franzone P., et al. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. Radiother Oncol 66 (2003) 151-157
46. Lamb D.S., Denham J.W., Mameghan H., et al. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol 68 (2003) 255-267
47. Martinez A.A., Demanes D.J., Galalae R., et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 62 (2005) 1322-1331
48. Roach III M., Lu J., Pilepich M.V., et al. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47 (2000) 617-627
49. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
50. Shipley W.U., Lu J.D., Pilepich M.V., et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 54 (2002) 1302-1310
51. Mottet N., Prayer-Galetti T., Hammerer P., et al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 98 (2006) 20-27